Human xylosyltransferase I (XT-I) initiates the biosynthesis of the glycosaminoglycan (GAG) linkage tetrasaccharide in proteoglycans. Xylosyltransferase II (XT-II) is a protein homologous to XT-I but with hitherto unknown activity or physiological function. Here, we report the enzymatic activity of XT-II and provide evidence that XT-II initiates the biosynthesis of both heparan sulfate and chondroitin sulfate GAGs. Transfection of the xylosyltransferase-deficient Chinese hamster ovary mutant pgsA-745 with XT-I or XT-II coding cDNA completely restored GAG biosynthesis. GAG disaccharide analysis revealed that XT-I-and XT-II-transfected pgsA-745 cells produced similar amounts of chondroitin sulfate and heparan sulfate. Furthermore, a high xylosyltransferase activity was measured after transfection with cDNAs encoding either isozyme. Analysis of the enzyme activity revealed that XT-II catalyzes the transfer of xylose to similar peptide acceptors as XT-I but with different efficiency. The optimal XT-II acceptor was observed using a bikunin-related peptide (K m 5.2 M). Analysis of XT-I and XT-II mRNA expression in murine tissues showed a differential expression pattern for both enzymes. In particular, XT-II is highly expressed in liver tissue, where XT-I transcripts were not detected. This is the first report on the enzyme activity of XT-II and its involvement in chondroitin sulfate and heparan sulfate biosynthesis.
Proteoglycans are a large group of polyanionic glycoproteins expressed in virtually every animal cell on the cell surface and in the extracellular matrix (1) . These abundant molecules serve a wide range of functions in many biological processes, including extracellular matrix deposition, cell-cell interactions, tumor cell growth, viral infections, and neurite outgrowth. They consist of a core protein to which varying numbers and types of glycosaminoglycan (GAG) 2 chains are covalently attached (2) . The biological roles of proteoglycans are closely related to the presence and biosynthesis of the GAG chains, which contain binding sites for various growth factors and matrix proteins.
The glycosaminoglycans chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin are bound to the proteoglycan core protein by a common linkage tetrasaccharide composed of D-GlcA␤1,3-Gal␤1,3Gal␤1,4Xyl-D-glucuronic acid-␤1,3-galactose-␤1,3-galactose-␤1,4-xylose- (2) . The initial transfer of D-xylose from UDP-D-xylose to specific serine residues of the core protein is catalyzed by one or more xylosyltransferases. Xylosyltransferase I (UDP-D-xylose:proteoglycan core protein ␤-D-xylosyltransferase I, EC 2.4.2.26, XT-I) was shown to be the rate-limiting step enzyme in the biosynthesis of GAG chains (3) . Furthermore, serum xylosyltransferase activity was found to be a biochemical marker for the assessment of disease activity in systemic sclerosis (4) and for the diagnosis of fibrotic remodeling processes, which are characterized by an elevated proteoglycan biosynthesis (5, 6) . In 2000, we successfully isolated the human XT-I from 2,000 liters of JAR choriocarcinoma cell culture supernatant and determined the partial amino acid sequence of the proteolytically cleaved protein (7, 8) . We cloned the cDNA of the human, mouse, and rat XT-I (9) and demonstrated that the recombinant human XT-I is the chain-initiating enzyme in proteoglycan biosynthesis (9, 10) .
We also cloned a cDNA encoding a putative protein highly homologous to the human XT-I, which was termed XT-II (9) . Both amino acid sequences have a 55% overall sequence identity. In addition, highly homologous regions with more than 80% identical amino acids are present (9) . All higher organisms have been found to harbor two xylosyltransferase genes, whereas Drosophila melanogaster and Caenorhabditis elegans have only one xylosyltransferase (11) (12) (13) . However, no enzymatic activity has been shown for XT-II and, consequently, the physiological function of this protein has remained a mystery. Nevertheless, we could already present evidence that XT-II is of * The work was supported by the Stiftung fü r Pathobiochemie und Molekulare Diagnostik of the Deutsche Vereinte Gesellschaft fü r Klinische Chemie und Laboratoriumsmedizin and by the Fakultät fü r Chemie of the Universität Bielefeld and National Institutes of Health grant GM33063 (to J. D. E.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. biological importance since mutations in the XT-II gene are genetic risk factors for diseases that are characterized by an altered proteoglycan metabolism, such as pseudoxanthoma elasticum (14) , osteoarthritis (15) , or diabetic nephropathy (16) .
In the present study, we transfected xylosyltransferase-deficient pgsA-745 CHO cells with human XT-I and XT-II cDNA to restore proteoglycan biosynthesis and to elucidate the physiological function of XT-II. XT-II is an active xylosyltransferase that is capable of restoring the GAG chain biosynthesis in mutant CHO cells, and XT-I and XT-II are differentially expressed in animal tissues. This is the first report on the physiological function of human XT-II and its involvement in the proteoglycan biosynthesis.
EXPERIMENTAL PROCEDURES
Radiochemical Xylosyltransferase Activity Assay-The method for determining xylosyltransferase activity is based on the incorporation of D-[
14 C]xylose with silk, recombinant bikunin, or bikunin peptides as the acceptor and was performed as described previously (17, 18) . For the determination of the K m values, various concentrations of the acceptor proteins were incubated with XT-II solution under assay conditions.
Analysis of Xylosyltransferase Activity by HPLC Electrospray Ionization Tandem Mass Spectrometry-For the determination of xylosyltransferase activity by HPLC electrospray ionization tandem mass spectrometry, the xylosyltransferase-mediated incorporation of UDP-xylose into the synthetic peptide biotin-NH-QEEEGSGGGQKK(5-fluorescein)-CONH 2 was quantified as described recently (19) . The characterization of the XT-I and XT-II reaction products was performed as described using the biotin-NH-QEEEGSGGGQKK(5-fluorescein)-CONH 2 as acceptor (9) .
Biotinylation of FGF-2-The biotinylation of FGF-2 was performed as described previously (20, 21) (22) were grown in Ham's F12 medium supplemented with 10% fetal calf serum under standard conditions. pgsA-745 CHO cells were transfected with the plasmids pSS1 and pCMV6-XL6-XYLT2 using FuGENE 6 transfection reagent (Roche Applied Science, Mannheim, Germany), as recommended by the manufacturer. pSS1 encodes a green fluorescent protein-tagged form of the fulllength human XT-I (23), and pCMV6-XL6-XYLT2 (GenBank TM accession number NM_022167, TrueClone, Origene, Rockville, MD) contains the complete cDNA of the full-length human XT-II. Stable transfectants were selected with 400 g/ml Geneticin (Invitrogen), and single clones were isolated. Flow cytometry analysis of FGF-2 binding was performed as described in the Supplemental Data.
Recombinant Expression of XT-II in the Yeast Pichia pastoris-A cDNA fragment encoding the amino acids 37-865 of the human XT-II was cloned in the pPICZ␣A vector, and the soluble form of XT-II was expressed in P. pastoris using standard conditions. The culture medium was harvested after 24 h, and the enzyme activity was analyzed. Mock-transfected cells were used as control.
HPLC Analysis of Chondroitin Sulfate and Heparan Sulfate Disaccharides-The isolation of GAG chains was performed as described in the Supplemental Data. 2-Amino-acridone labeling of GAG disaccharides and HPLC analysis were carried out as described previously (24, 25) . Analysis of XT-II Amino Acid Sequences-Homology analysis of the amino acid sequences of the XT-II was carried out using sequences extracted form the GenBank, Swissprot, or Ensembl databases. The sequences and the procedures are listed in the Supplemental Data.
Real-time Quantitative RT-PCR Analysis of Xylosyltransferase Expression in Murine Tissues

RESULTS AND DISCUSSION
Homology Analysis of Xylosyltransferase II Orthologs and
Identification of Highly Conserved Sequence Blocks-All higher organisms were found to possess two putative xylosyltransferase genes based on surveys of available genome sequences. Using the ClustalX alignment method, a sequence alignment of the XT-II peptide sequences from multiple organisms was performed. The XT-II was highly conserved among all species (Fig.  1) . XT-II of human and apes showed more than 98% amino acid sequence identity, whereas the XT-II sequence from other organisms were 60 -93% identical, with a much higher portion of amino acids with similar physicochemical properties. Interestingly, large conserved sequence blocks that contained identical amino acids among all XT-II sequences could be identified (Fig.  1B) . These comprised the transmembrane domain (amino acids 14 -38) and large stretches of the protein indicated by the rectangles in the figure. Furthermore, the carboxyl-terminal DXD motif, which is located at positions 651-653 in human XT-II and which was found to be important for enzyme activity in XT-I (11), is also situated in the fourth conserved sequence block. The carboxyl-terminal 25 amino acids of the XT-II are highly conserved, which is in accord with previous findings, indicating that this region was necessary for catalytic activity or enzyme stability in Drosophila and C. elegans xylosyltransferases (13, 26) . These findings clearly show that XT-II is an evolutionarily highly conserved glycosyltransferase like XT-II homologs (9, 11, 27) . Analysis of the gene structure and size of the XT-II genes in different organisms revealed that they consist of 11 exons with highly conserved exonintron borders (Fig. 1A) .
Differential mRNA Expression of the Xylosyltransferases-
The expression of XT-II and XT-I was analyzed in various murine tissues using a real-time RT-PCR-based method with normalized cDNA. The mRNA abundance of the target genes XYLT-I and XYLT-II was determined relative to the housekeeping genes encoding GAPDH, phospholipase A2, and ␤-actin. The highest expression level of XT-II was found in liver tissue, where the mRNA abundance was more than 2-fold higher than the average XT-II expression level in all eight organs (Fig. 2) . High XT-II mRNA levels could also be detected in the lung and the kidney. On the other hand, XT-I was highly expressed in mouse testis, kidney, and brain. Interestingly, no XT-I mRNA was detectable in liver tissue (Fig. 2) . The expression levels of both target genes in the investigated mouse tissues varied up to 10-fold. These findings support the conclusion that XT-I and XT-II have a tissue-specific expression pattern.
Expression of XT-I and XT-II mRNA in Mutant pgsA-745 CHO
Cells-pgsA-745 is a xylosyltransferase-deficient mutant CHO cell line that was reported to have less than 5% of the XT activity found in wild-type CHO-K1 cells (22) . However, the genetic basis of the proteoglycan biosynthesis deficiency in pgsA-745 is hitherto unknown. As the Chinese hamster was hypothesized to harbor two xylosyltransferase genes, we analyzed whether the expression of the XT genes is affected in pgsA-745 cells. An RT-PCR approach with oligonucleotides derived from the mouse XT-I and XT-II mRNA sequence and CHO-K1 cDNA was applied to identify the hamster XT-I and XT-II cDNA. Amplicons spanning the putative exons 3-8 of the XT-I gene and the exons 6 -11 of the XT-II gene were generated, sequenced, and used for the design of hamsterspecific XT-I and XT-II cDNA primers. The sequence identity between the mouse and hamster XT-I and XT-II cDNA sequences was 92 and 91%, respectively. Quantification of XT-I and XT-II mRNA showed that XT-II is the predominant isoform present in CHO wildtype cells (ratio of XT-I/GAPDH, 1:574 copies; ratio of XT-II/ GAPDH, 1.3:1 copies). The relative abundance of XT-I and XT-II mRNA in wild-type and pgsA-745 CHO cells was then quantified. XT-I transcripts were detected in wild-type cells but not in pgsA-745 cells. Furthermore, XT-II expression was 2.3-fold reduced when compared with wild-type cells, indicating that both genes are affected in the XT-deficient cell line pgsA-745. These results lead to the conclusion that multiple mutations in both XT genes are responsible for the XT deficiency of pgsA-745. Either promoter mutations or premature stop codons leading to nonsense-mediated decay (28) and a decreased mRNA stability are valid explanations for the absence of XT-I mRNA and the marked reduction of XT-II mRNA in pgsA-745 cells. However, further hitherto unidentified missense mutations that result in an inactive XT-II enzyme are proposed to be present in these cells.
Restoration of GAG Synthesis by Human XT-I and XT-II cDNA Expressed in Xylosyltransferase-deficient CHO Mutant
pgsA-745-The xylosyltransferase-deficient mutant CHO cell line pgsA-745 is not capable of synthesizing chondroitin or heparan sulfate (22) . It has been recently shown that the GAG FIGURE 1. Homology analysis of xylosyltransferase II orthologs. A, shows the phylogenetic tree of the XT-II protein sequences from multiple organisms when compared with lower model organisms with apparently only one xylosyltransferase gene present in the genome. The calculated molecular weight and the proportion of identical residues between the human XT-II sequence and the other xylosyltransferase sequences in this alignment are shown. B, illustrates the conserved sequence blocks and the presence of the transmembrane domain in the human XT-II sequence (amino acids 14 -38). Conserved sequence blocks were defined to contain identical amino acids in all but one XT-II sequence. The carboxyl-terminal DXD motif at positions 651-653 is located in the fourth conserved sequence block and is marked by a dark gray shaded box.
biosynthesis capacity of pgsA-745 can be restored by recombinant C. elegans XT (13). Here we transfected pgsA-745 CHO cells with human XT-I and XT-II cDNA and analyzed the GAGdependent binding of FGF-2 to the cell surface. Clonal cell lines stably expressing XT-I or XT-II were generated and showed a full restoration of FGF-2 binding to heparan sulfate on the cell surface (Fig. 3) . No significant differences between XT-I-and XT-II-expressing clones were observed. FGF-2 binding to the cell surface could be completely blocked by the addition of unfractionated heparin in wild-type and pgsA-745-XT-I and pgsA-745-XT-II cells yielding mean fluorescence values identical to the corresponding samples without the addition of FGF-2. Furthermore, pgsA-745-XT-I and pgsA-745-XT-II cells synthesize comparable amounts and types of GAG chains (Fig.  4) . These findings suggest that both xylosyltransferases can participate in the biosynthesis of heparan sulfate and chondroitin sulfate chains and that they are capable of compensating a cellular deficiency of either one xylosyltransferase or both xylosyltransferases.
Expression of human XT-I and human XT-II in pgsA-745 cells also resulted in restoration of xylosyltransferase activity. These data show that both enzymes were predominantly secreted (Table 1) . It has been shown previously that XT-I is shed from the Golgi surface and is released into the extracellular space together with large proteoglycans (4, 23) . Our present results now demonstrate that XT-II is also secreted into the culture supernatant. Although a regulatory role in proteoglycan trafficking has been proposed, the biological role of this secretion process remains to be elucidated.
In addition, expression of soluble XT-II lacking the transmembrane domain in the yeast P. pastoris resulted in a high XT activity in the culture supernatant (3589 Ϯ 186 milliunits/l, Fig.  4 ). In the mock-transfected control cells, no XT activity could be detected (detection limit Ͻ1 milliunits/l), confirming that XT-II has xylosyltransferase activity.
Kinetic analysis of the human XT-II expressed in pgsA-745-XT-II cells revealed that XT-II catalyzes the xylosylation of similar acceptor peptides as human XT-I but with different acceptor affinities. The bikunin-homologous peptide biotin-NH-QEEEGSGGGQKK(5-fluorescein)-CONH 2 (19) is the best substrate known so far for XT-IImediated xylosylation (K m 5.2 Ϯ 0.5 M). The Michaelis-Menten constant for recombinant bikunin was determined to be 22 Ϯ 2 M. The FGF-2-(1-24) peptide, which is homologous to the amino-terminal 24 amino acids of FGF-2 and which has been shown to be a good XT-I acceptor (29) , is also recognized by XT-II (K m 62 Ϯ 21 M). Furthermore, silk fibroin is a low affinity acceptor for XT-II (K m 677 Ϯ 191 M). The relative activity of XT-II for different peptide and protein substrates is shown in Fig. 4 . To identify the reaction products, the bikunin-homologous peptide was xylosylated by either recombinant XT-I or recombinant XT-II and subsequently subjected to the linkage-specific digestion of the bound xylose with ␣-xylosidase, ␤-xylosidase, and alkaline ␤-elimination. In all samples, the incorporated xylose could be released from the peptide by ␤-xylosidase treatment and alkaline ␤-elimination but not by incubation with ␣-xylosidase. These results demonstrate that the xylose residue was transferred to the hydroxyamino acid serine of the peptide through a ␤-linkage and that both XT-I and XT-II are UDP-Dxylose:proteoglycan core protein ␤-D-xylosyltransferases (EC 2.4.2.26).
Conclusion-Although the XT-II gene was already described by us in 2000 (9) , the XT-II enzymatic activity remained unknown for a long time. So far, only an inexplicit description of preliminary data was published, which suggested a potentially low level XT-II-mediated transfer of xylose to a perlecan peptide (30) . Here we can now present for the first time evidence that XT-II is a xylosyltransferase that is involved in the biosynthesis of heparan sulfate and chondroitin sulfate proteoglycans. Our experiments show that transfection of either XT-I or XT-II cDNA leads to a complete rescue of the proteoglycanbiosynthesis capacity of pgsA-745 CHO cells. Furthermore, our initial results prove that both enzymes utilize similar acceptors for xylosylation but with different acceptor affinities. Marked differences in the tissue-specific expression pattern of XT-I and XT-II were noticed; for example, XT-II is the only xylosyltransferase present in liver tissues. To summarize, these findings let us conclude that XT-I and XT-II are highly similar xylosyltransferases with tissue-specific expression patterns and that both 
TABLE 1
Xylosyltransferase activities in CHO cell lines 100,000 cells were seeded into 100-mm dishes and grown for 7 days. Cell culture supernatants and cells were then harvested and lysed, and the xylosyltransferase activity was measured using the HPLC electrospray ionization tandem mass spectrometry assay. The values shown are mean values Ϯ standard deviation. ND, not detected, detection limit 0.1 microunits/well; NA, not applicable; Mock, mocktransfected; EC, extracellular; IC, intracellular. enzymes are involved in the posttranslational biosynthesis of the tetrasaccharide linkage region in proteoglycans. The presence of two xylosyltransferase genes in all higher organisms points to the importance of these enzymes for essential cellular functions. In addition, no human disease is known so far that is caused by a loss-of-function defect of any of the xylosyltransferases. However, mutations in the XT-II gene have been shown to be genetic risk factors for diseases that are associated with an altered proteoglycan metabolism (14 -16) . For example, we could show that the XT-II gene mutation c.166G 3 A (p.D56N) leads to a more than 13-fold increased risk of a severe disease course and multiple organ effects in pseudoxanthoma elasticum patients (14) .
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